Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products.
All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. Past performance doesn't necessarily make one stock better than the other, though. Which of these big pharma stocks is the smarter pick for investors now? Here's how AbbVie and GlaxoSmithKline compare.
Image source: Getty Images.
Source: Fool.com
GSK plc ADR Aktie
36,00 €
-2,70 %
Die Community bevorzugt GSK plc ADR mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein Kursziel von 49 € für GSK plc ADR würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 36.0 € bedeuten.
